Drug Trial Radar · NCT05529849
A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects
Last checked: Nov 19, 2026Latest source record: Feb 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Jul 12, 2022
Primary completion
Dec 12, 2022
Study completion Feb 20, 2023
Sponsor
- Lead sponsor
- Endevica BioIndustry
- Sponsor type
- Industry
- First posted
- Sep 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will test an experimental drug named TCMCB07 for the treatment of cancer cachexia. Cachexia is a syndrome characterized by weight loss, anorexia, weakness or lack of energy, and anemia. Cachexia occurs in many cancers, usually at the advanced stages of disease.
Conditions
- Cachexia
Interventions
TCMCB07Drug
Subcutaneous injection of TCMCB07
PlaceboDrug
Matching subcutaneous placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of people with an Adverse Event AssessmentTime frame: 6 Months
- Number of participants with abnormal vital signsTime frame: 6 Months
- Number of people with abnormal laboratory test resultsTime frame: 6 Months
- Number of people with abnormal ElectrocardiogramsTime frame: 6 Months
- Number of people with abnormal physical examinationsTime frame: 6 Months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences -- Miami, Inc.
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.